375 related articles for article (PubMed ID: 27054314)
1. Immune checkpoint inhibitors: a patent review (2010-2015).
Collin M
Expert Opin Ther Pat; 2016 May; 26(5):555-64. PubMed ID: 27054314
[TBL] [Abstract][Full Text] [Related]
2. Inhibitors of programmed cell death 1 (PD-1): a patent review (2010-2015).
Zarganes-Tzitzikas T; Konstantinidou M; Gao Y; Krzemien D; Zak K; Dubin G; Holak TA; Dömling A
Expert Opin Ther Pat; 2016 Sep; 26(9):973-7. PubMed ID: 27367741
[No Abstract] [Full Text] [Related]
3. Immune checkpoint protein inhibition for cancer: preclinical justification for CTLA-4 and PD-1 blockade and new combinations.
Baksh K; Weber J
Semin Oncol; 2015 Jun; 42(3):363-77. PubMed ID: 25965355
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic bispecific antibody formats: a patent applications review (1994-2017).
Godar M; de Haard H; Blanchetot C; Rasser J
Expert Opin Ther Pat; 2018 Mar; 28(3):251-276. PubMed ID: 29366356
[TBL] [Abstract][Full Text] [Related]
5. Cancer immunotherapy using anti-TIM3/PD-1 bispecific antibody: a patent evaluation of EP3356411A1.
Herrera-Camacho I; Anaya-Ruiz M; Perez-Santos M; Millán-Pérez Peña L; Bandala C; Landeta G
Expert Opin Ther Pat; 2019 Aug; 29(8):587-593. PubMed ID: 31241380
[No Abstract] [Full Text] [Related]
6. Anti-programmed death-1 and anti-programmed death-ligand 1 antibodies in cancer therapy.
Hamid O; Carvajal RD
Expert Opin Biol Ther; 2013 Jun; 13(6):847-61. PubMed ID: 23421934
[TBL] [Abstract][Full Text] [Related]
7. Checkpoint blocking antibodies in cancer immunotherapy.
Kyi C; Postow MA
FEBS Lett; 2014 Jan; 588(2):368-76. PubMed ID: 24161671
[TBL] [Abstract][Full Text] [Related]
8. PD-1/PD-L1 inhibitors.
Sunshine J; Taube JM
Curr Opin Pharmacol; 2015 Aug; 23():32-8. PubMed ID: 26047524
[TBL] [Abstract][Full Text] [Related]
9. Predictive biomarkers in PD-1/PD-L1 checkpoint blockade immunotherapy.
Meng X; Huang Z; Teng F; Xing L; Yu J
Cancer Treat Rev; 2015 Dec; 41(10):868-76. PubMed ID: 26589760
[TBL] [Abstract][Full Text] [Related]
10. Current Perspectives in Immunotherapy for Non-Small Cell Lung Cancer.
Garon EB
Semin Oncol; 2015 Oct; 42 Suppl 2():S11-8. PubMed ID: 26477470
[TBL] [Abstract][Full Text] [Related]
11. Global patent landscape of programmed cell death 1: implications of the rapid expansion.
Kong X; Zhang Q; Lai Y; Hu H; Chen X; Hu Y
Expert Opin Ther Pat; 2018 Jan; 28(1):69-80. PubMed ID: 28891360
[TBL] [Abstract][Full Text] [Related]
12. Predictive biomarkers for programmed death-1/programmed death ligand immune checkpoint inhibitors in nonsmall cell lung cancer.
Remon J; Chaput N; Planchard D
Curr Opin Oncol; 2016 Mar; 28(2):122-9. PubMed ID: 26756384
[TBL] [Abstract][Full Text] [Related]
13. Checkpoint Inhibition: Programmed Cell Death 1 and Programmed Cell Death 1 Ligand Inhibitors in Hodgkin Lymphoma.
Villasboas JC; Ansell S
Cancer J; 2016; 22(1):17-22. PubMed ID: 26841012
[TBL] [Abstract][Full Text] [Related]
14. Intellectual property issues of immune checkpoint inhibitors.
Storz U
MAbs; 2016; 8(1):10-26. PubMed ID: 26466763
[TBL] [Abstract][Full Text] [Related]
15. Programmed death-1 & its ligands: promising targets for cancer immunotherapy.
Shrimali RK; Janik JE; Abu-Eid R; Mkrtichyan M; Khleif SN
Immunotherapy; 2015; 7(7):777-92. PubMed ID: 26250412
[TBL] [Abstract][Full Text] [Related]
16. CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients.
Ott PA; Hodi FS; Robert C
Clin Cancer Res; 2013 Oct; 19(19):5300-9. PubMed ID: 24089443
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies.
Philips GK; Atkins M
Int Immunol; 2015 Jan; 27(1):39-46. PubMed ID: 25323844
[TBL] [Abstract][Full Text] [Related]
18. Endocrinopathies induced by immune-checkpoint inhibitors in advanced non-small cell lung cancer.
Rossi E; Sgambato A; De Chiara G; Casaluce F; Losanno T; Sacco PC; Santabarbara G; Gridelli C
Expert Rev Clin Pharmacol; 2016; 9(3):419-28. PubMed ID: 26681547
[TBL] [Abstract][Full Text] [Related]
19. Emerging drugs targeting PD-1 and PD-L1: reality or hope?
Casaluce F; Sgambato A; Sacco PC; Palazzolo G; Maione P; Rossi A; Ciardiello F; Gridelli C
Expert Opin Emerg Drugs; 2014 Dec; 19(4):557-69. PubMed ID: 25253438
[TBL] [Abstract][Full Text] [Related]
20. Drug of the year: programmed death-1 receptor/programmed death-1 ligand-1 receptor monoclonal antibodies.
Robert C; Soria JC; Eggermont AM
Eur J Cancer; 2013 Sep; 49(14):2968-71. PubMed ID: 23907003
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
